Dong Xue1, Hong Sun, Ping-Ping Li. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrative Medicine, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.
Abstract
OBJECTIVE: To evaluate the effect of Chinese herbs decoction Shu-Gan-Liang-Xue on endocrine therapy- associated hot flashes symptom in breast cancer patients. METHODS: Sixty-six patients with breast cancer receiving adjuvant endocrine therapy were categorized to two groups, the control group received endocrine therapy alone, the other group is administered with Chinese herbs decoction Shu-Gan-Liang-Xue besides the endocrine therapy: Shu-Gan-Liang-Xue decoction was administered above 6 months per year for more than 2 years. Frequency of hot flashes per day was recorded, and the effect of Shu-Gan-Liang-Xue decoction on hot flashes symptom being assessed with Kupperman Scoring Index. RESULTS: Sixty cases were analyzed, 32 cases in endocrine therapy combining Chinese herbs decoction group, 28 cases in mere endocrine therapy group. For hot flashes symptom, in Chinese herbs decoction administration group, 7 cases (21.9%) reported symptom disappeared, 22 cases (68.7%) reported symptom alleviated, 3 cases (9.4%) reported symptom not changed; in endocrine therapy alone group, 5 cases (17.9%) reported symptom disappeared, 13 cases (46.4%) reported symptom alleviated, 10 cases (10/28, 35.7%) reported symptom not changed. The difference between two groups was statistically significant (P=0.013). For sleeping disorder, in Chinese herbs decoction administration group, 27 cases (84.4%) reported symptom improved, 5 cases (15.6%) reported no change; in endocrine therapy alone group, 16 cases (57.1%) symptom improved, 12 cases (42.9%) reported no change in sleeping disorder (P=0.019), the difference was also of significance statistically. CONCLUSION: Long-term Chinese herbs decoction administration remarkably improved hot flashes symptom and sleeping disorder associated with endocrine therapy, meanwhile without definite toxicity and influence on the risk of recurrence of tumor.
OBJECTIVE: To evaluate the effect of Chinese herbs decoction Shu-Gan-Liang-Xue on endocrine therapy- associated hot flashes symptom in breast cancerpatients. METHODS: Sixty-six patients with breast cancer receiving adjuvant endocrine therapy were categorized to two groups, the control group received endocrine therapy alone, the other group is administered with Chinese herbs decoction Shu-Gan-Liang-Xue besides the endocrine therapy: Shu-Gan-Liang-Xue decoction was administered above 6 months per year for more than 2 years. Frequency of hot flashes per day was recorded, and the effect of Shu-Gan-Liang-Xue decoction on hot flashes symptom being assessed with Kupperman Scoring Index. RESULTS: Sixty cases were analyzed, 32 cases in endocrine therapy combining Chinese herbs decoction group, 28 cases in mere endocrine therapy group. For hot flashes symptom, in Chinese herbs decoction administration group, 7 cases (21.9%) reported symptom disappeared, 22 cases (68.7%) reported symptom alleviated, 3 cases (9.4%) reported symptom not changed; in endocrine therapy alone group, 5 cases (17.9%) reported symptom disappeared, 13 cases (46.4%) reported symptom alleviated, 10 cases (10/28, 35.7%) reported symptom not changed. The difference between two groups was statistically significant (P=0.013). For sleeping disorder, in Chinese herbs decoction administration group, 27 cases (84.4%) reported symptom improved, 5 cases (15.6%) reported no change; in endocrine therapy alone group, 16 cases (57.1%) symptom improved, 12 cases (42.9%) reported no change in sleeping disorder (P=0.019), the difference was also of significance statistically. CONCLUSION: Long-term Chinese herbs decoction administration remarkably improved hot flashes symptom and sleeping disorder associated with endocrine therapy, meanwhile without definite toxicity and influence on the risk of recurrence of tumor.
Entities:
Keywords:
Breast cancer; Chinese herbs decoction; Endocrine therapy; Hot flashes; Tamoxifen
Authors: J S Jacobson; A B Troxel; J Evans; L Klaus; L Vahdat; D Kinne; K M Lo; A Moore; P J Rosenman; E L Kaufman; A I Neugut; V R Grann Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: J S Carpenter; M A Andrykowski; M Cordova; L Cunningham; J Studts; P McGrath; D Kenady; D Sloan; R Munn Journal: Cancer Date: 1998-05-01 Impact factor: 6.860
Authors: S K Quella; C L Loprinzi; J A Sloan; N L Vaught; W L DeKrey; T Fischer; G Finck; N Pierson; T Pisansky Journal: Cancer Date: 1998-05-01 Impact factor: 6.860
Authors: Patricia A Ganz; Katherine A Desmond; Beth Leedham; Julia H Rowland; Beth E Meyerowitz; Thomas R Belin Journal: J Natl Cancer Inst Date: 2002-01-02 Impact factor: 13.506
Authors: Cheri L Van Patten; Ivo A Olivotto; G Keith Chambers; Karen A Gelmon; T Gregory Hislop; Edith Templeton; Angela Wattie; Jerilynn C Prior Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Philippe Debourdeau; Thomas Bachelot; Christine Zammit; Marc Aletti; Cyrille Gallineau; Joseph Gligorov Journal: Bull Cancer Date: 2004-04 Impact factor: 1.276